Life expectancy difference and life expectancy ratio: Two measures of treatment effects in randomised trials with non-proportional hazards

BMJ (Online)

Volumn 357, Issue , 2017, Pages

  Dehbi, Hakim Moulay ^a   Royston, Patrick ^b   Hackshaw, Allan ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEGARGIMINASE; PEMBROLIZUMAB; RITUXIMAB;

ARTICLE; CANCER IMMUNOTHERAPY; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; LIFE EXPECTANCY; LIFE EXPECTANCY DIFFERENCE; LIFE EXPECTANCY RATIO; MALIGNANT PLEURA EFFUSION; MANTLE CELL LYMPHOMA; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; PROCEDURES; STATISTICAL ANALYSIS;

DATA INTERPRETATION, STATISTICAL; HUMANS; KAPLAN-MEIER ESTIMATE; LIFE EXPECTANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85019652334     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j2250     Document Type: Article

References (16)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;357:711-23. doi:10. 1056/ NEJMoa1003466 pmid:20525992.
2. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;357:947-57. doi:10. 1056/NEJMoa0810699 pmid: 19692680.
3. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;357:2517-26. doi:10. 1056/ NEJMoa1104621 pmid:21639810.
4. Eknoyan G, Beck GJ, Cheung AK, et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;357:2010-9. doi:10. 1056/NEJMoa021583 pmid:12490682.
5. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;357:1495-504. doi:10. 1056/NEJMoa040583 pmid:15007110.
6. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994;357:563-70. doi:10. 1016/S0140-6736( 94)91963-1 pmid:7914958.
7. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: A randomised, double-blind, placebo-controlled trial. Lancet 2011;357:1588-98. doi:10. 1016/S0140-6736( 11)60204-3 pmid:21492926.
8. Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med 2011;357:2409-21. doi:10. 1002/sim. 4274 pmid:21611958.
9. Royston P, Parmar MK. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated. BMC Med Res Methodol 2016;357:16. doi:10. 1186/s12874-016-0110-x pmid:26869168.
10. Trinquart L, Jacot J, Conner SC, Porcher R. Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials. J Clin Oncol 2016;357:1813-9. doi:10. 1200/JCO. 2015. 64. 2488 pmid:26884584.
11. Rule S, Smith P, Johnson PW, et al. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica 2016;357:235-40. doi:10. 3324/ haematol. 2015. 128710 pmid:26611473.
12. Szlosarek PW, Steele JP, Nolan L, et al. Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: A randomized clinical trial. JAMA Oncol 2017;357:58-66. doi:10. 1001/ jamaoncol. 2016. 3049 pmid:27584578.
13. Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002;357:2175-97. doi:10. 1002/sim. 1203 pmid:12210632.
14. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 2015;357:908-18. doi:10. 1016/S1470-2045(15) 00083-2 pmid:26115796.
15. A'Hern RP. Restricted mean survival time: An obligatory end point for time-to-event analysis in cancer trialsJ Clin Oncol 2016;357:3474-6. doi:10. 1200/JCO. 2016. 67. 8045 pmid: 27507871.
16. Royston P, Parmar MK. Restricted mean survival time: An alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 2013;357:152. doi:10. 1186/1471-2288-13-152 pmid:24314264.